• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Medicinova Inc

    4/28/25 4:16:03 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNOV alert in real time by email
    DEFA14A 1 notice_card_2025_defa14a.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the Securities

    Exchange Act of 1934 (Amendment No. )

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material Pursuant to §240.14a-12

     

     

    MEDICINOVA, INC

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒ No fee required

    ☐ Fee paid previously with preliminary materials

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

     

     

     

     

     


    img85605900_0.jpg


    img85605900_1.jpg


    Get the next $MNOV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MNOV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MNOV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025

      LA JOLLA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces that their CEO, Yuichi Iwaki, MD, Ph.D., and CBO, David H. Crean, Ph.D., will be participating in investor meetings at D. Boral Capital's, Inaugural DBC Conference on May 14, 2025 at the Plaza Hotel, New York City. The conference will bring together public and private executives with institutional investors, high-net worth individuals, and corporate clients from various sectors including Healthcare & Life Sciences. Drs. Iwaki and Crean will be discussing Me

      4/14/25 7:00:00 PM ET
      $MNOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

      LA JOLLA, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced enrollment of the first patient in the NIH-funded Expanded Access Program (EAP) trial to evaluate MN-166 (ibudilast) in patients with Amyotrophic Lateral Sclerosis (ALS). This significant milestone marks the beginning of a critical trial aimed at providing access to MN-166 for ALS patients who are not eligible for the ongoing Phase 2/3 COMBAT-ALS trial. The EAP trial, funded by the National Institutes of Health (NIH) - Neurological Disorders and Stroke (

      4/8/25 7:00:00 PM ET
      $MNOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

      LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the study update and interim analysis results from the Company's COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) will be presented at the 35th International Symposium on ALS/MND held December 6-8, 2024 in Montreal, Canada. The highlights of the presentation, titled, "COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Interim Analysis Results" (Abstract # 302), include: Study Update:

      12/5/24 6:00:00 PM ET
      $MNOV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNOV
    SEC Filings

    See more
    • SEC Form 10-Q filed by Medicinova Inc

      10-Q - MEDICINOVA INC (0001226616) (Filer)

      5/13/25 4:39:37 PM ET
      $MNOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Medicinova Inc

      DEFA14A - MEDICINOVA INC (0001226616) (Filer)

      4/28/25 4:16:03 PM ET
      $MNOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Medicinova Inc

      DEF 14A - MEDICINOVA INC (0001226616) (Filer)

      4/28/25 4:15:04 PM ET
      $MNOV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on MediciNova with a new price target

      Maxim Group initiated coverage of MediciNova with a rating of Buy and set a new price target of $15.00

      3/16/21 8:15:44 AM ET
      $MNOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on MediciNova with a new price target

      Maxim Group initiated coverage of MediciNova with a rating of Buy and set a new price target of $15.00

      3/10/21 7:48:19 AM ET
      $MNOV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Medicinova Inc (Amendment)

      SC 13D/A - MEDICINOVA INC (0001226616) (Subject)

      7/12/22 12:12:02 PM ET
      $MNOV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Nagao Hideki

      4 - MEDICINOVA INC (0001226616) (Issuer)

      2/14/25 4:54:40 PM ET
      $MNOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Matsuda Kazuko

      4 - MEDICINOVA INC (0001226616) (Issuer)

      2/14/25 4:52:26 PM ET
      $MNOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lemerond Nicole

      4 - MEDICINOVA INC (0001226616) (Issuer)

      2/14/25 4:51:32 PM ET
      $MNOV
      Biotechnology: Pharmaceutical Preparations
      Health Care